Argus analyst Jasper Hellweg keeps his Buy rating and $342 price target on Anthem, saying that while the company has gone on a run of 11 consecutive quarters of earnings beats, the stock has recently struggled due to concern about the potential impact of "Medicare for All." The analyst believes that these worries are "unwarranted" given the opposition to a single-payer medical coverage model in Congress and expects the company to benefit from "further enrollment gains, continued share buybacks, contributions from IngenioRx, and management's updated guidance." Hellweg adds that at 14.9-times his expected FY19 earnings, Anthem shares are undervalued.